Pantoprazole

Catalog No.S2105 Synonyms: SKFSKF96022, BY-1023

For research use only.

Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

Pantoprazole  Chemical Structure

CAS No. 102625-70-7

Selleck's Pantoprazole has been cited by 2 Publications

Purity & Quality Control

Choose Selective Proton Pump Inhibitors

Other Proton Pump Products

Biological Activity

Description Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.
Targets
(H+/K+)-ATPase [1]
()
Proton pump [1]
()
In vitro

PPZ(Pantoprazole) inhibits the proliferation of tumor cells, induces apoptosis and downregulates the expression of PKM2, which contributes to the current understanding of the functional association between PPZ and PKM2(The human M2 isoform of pyruvate kinase)[2]. Ex vivo studies showed that pantoprazole inhibited TOPK activities in JB6 Cl41 cells and HCT 116 colorectal cancer cells. Moreover, knockdown of TOPK in HCT 116 cells decreased their sensitivities to pantoprazole[3].

In vivo i.p. injection of pantoprazole in HCT 116 colon tumor-bearing mice effectively suppresses cancer growth. The TOPK downstream signaling molecule phospho-histone H3 in tumor tissues is also decreased after pantoprazole treatment[3]. At higher infusion rates, pantoprazole is able to induce negative hemodynamic responses, in particular, in the setting of heart failure. These effects can lead to significant impairment of cardiac function[4]. Also, pantoprazole delays fracture healing by affecting both bone formation and bone remodeling[5].

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: SGC-7901 cells
  • Concentrations: 5 mg/ml
  • Incubation Time: 24 h
  • Method:

    The SGC-7901 cells are seeded in 100 µl of medium per well, at a density of 1x104/well, in 96-well plates and treated with 5 mg/ml PPZ for 24 h. The cytotoxicity of PPZ is assessed by a cell counting kit-8 assay. The cytotoxicity is expressed as the relative cell viability, using the following formula: Cell viability (%) = (OD of drug-treated sample/OD of untreated sample) x 100. The experiment is repeated 3 times.

Animal Research:

[3]

  • Animal Models: Non-obese Diabetic/Severe Combined Immunodeficiency (NOD-SCID) mice
  • Dosages: 100 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

DMSO 76 mg/mL
(198.24 mM)
Ethanol 76 mg/mL
(198.24 mM)
Water Insoluble

Chemical Information

Molecular Weight 383.37
Formula

C16H15F2N3O4S

CAS No. 102625-70-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04248335 Recruiting Drug: Pantoprazole|Drug: Midazolam injection Pediatric Obesity|NAFLD|GERD Children''s Mercy Hospital Kansas City July 3 2018 Phase 4
NCT02401035 Recruiting Drug: IV pantoprazole Gastroesophageal Reflux Disease Pfizer May 9 2017 Phase 4
NCT02274961 Unknown status Drug: S-pantoprazole 10mg|Drug: Placebo Non Erosive Reflux Disease Ahn-Gook Pharmaceuticals Co.Ltd October 2014 Phase 3
NCT02186652 Completed Drug: Pantoprazole Gastroesophageal Reflux Disease Phillip Brian Smith|The Emmes Company LLC|Duke University June 4 2014 Phase 1
NCT01710462 Withdrawn Drug: Pantoprazole + Domperidone|Drug: Pantozol® Gastroesophageal Reflux Disease Eurofarma Laboratorios S.A. August 2013 Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Pantoprazole | Pantoprazole supplier | purchase Pantoprazole | Pantoprazole cost | Pantoprazole manufacturer | order Pantoprazole | Pantoprazole distributor